# Clinical-Trans-Valid Core

> **NIH NIH U54** · NORTHWESTERN UNIVERSITY · 2021 · $547,590

## Abstract

SUMMARY – CLINICAL TRANSLATION AND VALIDATION CORE
The C-THAN Clinical Translation and Validation Core (Clinical Trans Valid Core) will be robust and achievable
due to many years of HIV-focused clinical research and research training with local partners in Nigeria, South
Africa, Mali, and Tanzania. In addition to our key academic partners, we will integrate many other international,
national, regional and community stakeholders involved in POC development, validation, and implementation
across the partner institutions. Our overarching objective is to develop a pipeline of POC products that meet
the clinical needs of HIV-infected individuals in low and middle-income countries. Investigators will be required
to demonstrate analytical and clinical performance of technologies as well as suitability and feasibility of use in
low resource settings. The Clinical Trans Valid Core specific aims are: 1. validate and establish best practices
for innovative POC technologies developed for the diagnosis and management of HIV and HIV related co-
morbidities in “real-world” clinical or public health settings, 2. assess outcomes of implementation processes of
innovative POC technologies developed for the diagnosis and management of HIV and HIV related co-
morbidities in “real-world” clinical or public health settings, and 3. support translation of innovative POC
technologies from the Technology Development (Technology Dev) Core into clinical practice though pilot
funding, expertise in validation and implementation science, and providing resources including support to
develop needed trainings, manuals and other tools to ensure effective uptake. Our Clinical Trans Valid Core
will provide a “clinical laboratory” for innovators that will focus on validation, adoption, and assessment of
feasibility and implementation of POC technologies. Depending on the status of a developing POC
technology, we will work across Cores to select projects to participate in either the Clinical Trans Valid Core or
Technology Dev Core. We will also review projects in the Technology Dev Core in later stages for potential
transition into the Clinical Trans Valid Core. The primary goal of the Clinical Trans Valid Core is to provide
infrastructure and services dedicated to clinical validation of POC technologies and to evaluate implementation
outcomes including adoption, fidelity, feasibility and acceptability to ensure that POC technology prototypes
supported under C-THAN will have a high rate of success for clinical uptake and maximal public health impact.

## Key facts

- **NIH application ID:** 10174928
- **Project number:** 5U54EB027049-04
- **Recipient organization:** NORTHWESTERN UNIVERSITY
- **Principal Investigator:** Chad J Achenbach
- **Activity code:** U54 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $547,590
- **Award type:** 5
- **Project period:** 2018-09-11 → 2023-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10174928

## Citation

> US National Institutes of Health, RePORTER application 10174928, Clinical-Trans-Valid Core (5U54EB027049-04). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10174928. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*